NCI-H1975 CDX Model 

The NCI-H1975 cell line is derived from human non-small cell lung cancer (NSCLC), the predominant subtype of lung cancer, accounting for about 85% of all lung cancer cases. NSCLC can further be broken down into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, with varying molecular profiles and clinical behaviors. NCI-H1975 is notably characterized by specific mutations in the EGFR gene, making it a particularly useful model for studying targeted therapies for EGFR-mutant NSCLC. This cell line encapsulates key molecular features and genetic alterations typical of NSCLC patients, accentuating its relevance in preclinical investigations. In vitro and in vivo studies using NCI-H1975 provide crucial insights into tumor growth, metastatic potential, and responsiveness to EGFR-targeted therapies, as well as other therapeutic agents. Researchers widely utilize NCI-H1975 to decipher the molecular mechanisms underpinning NSCLC, evaluate novel therapeutic compounds, and explore mechanisms of resistance, especially in the context of EGFR inhibitors.

Model Details

Cancer Location: Lung
Cancer Type: Non-Small Cell Lung Cancer
Model Name: NCI-H1975
Mouse Strain: Nu/Nu, NSG
Treatment Data Available: Chemotherapy (Erlotinib, Pemetrexed)

NCI-H1975 Growth curves

Growth of subcutaneous NCI-H1975  in Nu/Nu  mice (n=8)

Request Additional Syngeneic Model Data

Contact Us

Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our
expert staff today to get started.

Skip to content